Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. | While Stéphane Bancel received a ...

Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

And the company isn't done. CEO Stéphane Bancel says that the goal is to eliminate close to $1 billion in costs by the end of this year. It's a good sign for investors, but it may not necessarily be ...

Wall Street rebondit grâce à l'exemption de droits de douane sur les véhicules La Bourse de New York a terminé en hausse ...

(AOF) - Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté pour 6 millions de dollars d’actions de la société.